硫酸沙丁胺醇缓释胶囊治疗儿童咳嗽变异性哮喘

目的：观察硫酸沙丁胺醇缓释胶囊（爱纳灵）治疗儿童咳嗽变异性哮喘临床症状控制的有效性、安全性.方法：采用随机开放性自身对照研究,选择2009年5月-2010年4月期间在广州医学院第一附属医院儿科门诊诊断为咳嗽变异性哮喘患儿46例,年龄范围5岁-13岁,其中男性25例,女性21例.入选者口服爱纳灵每次0.1～0.15 mg/kg,每日早、晚各1次,连续2周.观察期间,记录患儿的咳嗽日间症状评分、夜间症状评分及峰流速（PEF）监测,分别在治疗前、治疗第7天、第14天检查肺功能,记录1秒钟用力呼气量占正常预计值的百分比（FEV1％）及最高PEF占正常预计值的百分比（PEF％）,评估临床疗效评分及有效率,并记录不良反应.结果：在治疗后第7天、第14天观察点的咳嗽日间症状评分、夜间症状评分、FEV1％、PEF％、疗效分均较治疗前有明显改善,差异有统计学意义（P值均＜0.01）.临床总有效数为39例,总有效率为84.78％.在整个观察期,未发现用药不良反应.结论：爱纳灵为高选择性β2受体激动剂,在治疗咳嗽变异性哮喘中能较好地改善患儿的临床症状及肺功能,安全性较好,适用于儿童咳嗽变异性哮喘的治疗.

Clinical efficacy of etinoline in children with cough variant asthma (CVA) :an observational study

Abstract Objective：To investigate the efficacy and safety of salbutamol sulfate sustained release capsules （etinoline） in treatment of clinical symptoms among children with cough variant asthma （CVA）. Methods： Between May 2009 and April 2010, a randomized open-label self-control study was performed in 46 out-patients （25 males and 21 females, aged 5 to 13 yrs old） diagnosed with CVA in Department of Pediatrics, First Affiliated Hospital of Guangzhou. Medical： College. All patients were treated with twice-daily oral etinoline （0. 1 - 0. 15mg/kg/dose） after breakfast and dinner for 2 weeks. During the study period, daytime symptom scores, nighttime symptom scores and peak expiratory flow （PEF） were recorded in the patients. Moreover, pulmonary function test was performed at baseline, on days 7 and 14 after treatment. Forced expiratory volume in one second （FEVI%） and the highest percentage predicted PEF （PEF%） were calculated. The clinical efficacy and effective rate were then evaluated,as well as the adverse effects recorded. Results The daytime symptom scores, nighttime symptom scores, FEVI%, PEF% and efficacy scores in the patients were significantly improved at 7 and 14 days after treatment as compared with baseline （P 〈 0.01 ）. A total of 39 cases showed clinical response to the treatment （ overall rate of response = 84.78% ）. No adverse effects related to medication were found throughout the study. Conclusion：Etinoline as a highly selective β2 receptor agonist could favorably improve the clinical symptoms and pulmonary function of CVA children and thus may be indicative in treatment of this condition.